ArticleClinical and experimental nephrology2025
Human primary proximal tubular epithelial cells and sepsis: a scoping review.
Article in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Eryptosis in Acute Patients: A Hypothesis on Its Potential Clinical Impact and Current Gaps in Evidence.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis impairs proximal renal tubular epithelial cell (PTEC) function, and this impairment contributes to the pathophysiology of sepsis-associated acute kidney injury (SA-AKI). By closely replicating in vivo conditions, primary human PTEC offer superior biological relevance for studying SA-AKI. The purpose of this scoping review was to identify and investigate experiments, where human primary PTEC have been used to study sepsis-related factors.
methodsA comprehensive literature search strategy was developed, and our reported items adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews (PRISMA-ScR) checklist. Peer-reviewed articles published in English or Scandinavian languages between 1946 and 2024 were included.
resultsThe literature search provided 292 results. Twelve studies were included, out of which only two were published after 2010. Eight studies used human primary PTEC isolated from healthy tissue during tumor nephrectomy, while four studies used primary PTEC purchased from commercially available providers. Experimental methods were heterogenous. The included studies applied E. coli porine, E. coli, Staphylococcal enterotoxin B, cytokines and lipopolysaccharide with differing dosages, exposure lengths, and combinations.
conclusionsAlthough human primary PTEC more closely resembles the in vivo environment in human kidneys, their use in sepsis and SA-AKI research remains remarkably limited, leading to substantial research gaps in the field. In addition, there is significant heterogeneity in the methodologies employed across existing studies. Standardizing and expanding the use of primary PTECs in future in vitro research could be pivotal for unraveling novel and relevant insights into the pathophysiology of SA-AKI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.